Bafna [BAFNAPH] vs Aarey Drugs [AAREYDRUGS] Detailed Stock Comparison

Bafna Pharmaceuticals Ltd.

NSE
Loading...

Aarey Drugs & Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Bafna Pharmaceuticals Ltd. wins in 13 metrics, Aarey Drugs & Pharmaceuticals Ltd. wins in 5 metrics, with 0 ties. Bafna Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bafna Pharmaceuticals Ltd. Aarey Drugs & Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 32.31 72.40 Bafna Pharmaceuticals Ltd.
Price-to-Book Ratio 3.43 1.66 Aarey Drugs & Pharmaceuticals Ltd.
Debt-to-Equity Ratio 35.52 38.27 Bafna Pharmaceuticals Ltd.
PEG Ratio 0.34 -3.14 Bafna Pharmaceuticals Ltd.
EV/EBITDA 21.81 119.92 Bafna Pharmaceuticals Ltd.
Profit Margin (TTM) 6.55% 0.88% Bafna Pharmaceuticals Ltd.
Operating Margin (TTM) 3.87% -2.43% Bafna Pharmaceuticals Ltd.
EBITDA Margin (TTM) 3.87% N/A N/A
Return on Equity 4.90% 2.91% Bafna Pharmaceuticals Ltd.
Return on Assets (TTM) 2.71% 1.39% Bafna Pharmaceuticals Ltd.
Free Cash Flow (TTM) $2.76M $50.96M Aarey Drugs & Pharmaceuticals Ltd.
1-Year Return 138.52% 41.04% Bafna Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 2.18 0.64 Aarey Drugs & Pharmaceuticals Ltd.
Enterprise Value $3.53B $3.00B Bafna Pharmaceuticals Ltd.
EV/Revenue Ratio 2.40 0.77 Aarey Drugs & Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 28.78% -0.38% Bafna Pharmaceuticals Ltd.
Revenue per Share (TTM) $62 $137 Aarey Drugs & Pharmaceuticals Ltd.
Earnings per Share (Diluted) $4.09 $1.22 Bafna Pharmaceuticals Ltd.
Beta (Stock Volatility) -0.02 0.80 Bafna Pharmaceuticals Ltd.

Bafna Pharmaceuticals Ltd. vs Aarey Drugs & Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

BAFNAPH
AAREYDRUGS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bafna Pharmaceuticals Ltd.-10.00%40.06%46.95%81.30%38.27%30.72%
Aarey Drugs & Pharmaceuticals Ltd.0.41%3.28%-13.25%15.13%11.25%18.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bafna Pharmaceuticals Ltd.138.52%41.70%23.53%513.36%277.60%277.60%
Aarey Drugs & Pharmaceuticals Ltd.41.04%155.63%79.56%79.56%79.56%79.56%

Performance & Financial Health Analysis: Bafna Pharmaceuticals Ltd. vs Aarey Drugs & Pharmaceuticals Ltd.

MetricBAFNAPHAAREYDRUGS
Market Information
Market Cap i₹3.34B₹2.50B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i6,280287,283
90 Day Avg. Volume i5,379157,618
Last Close₹174.58₹80.24
52 Week Range₹72.01 - ₹213.36₹50.31 - ₹100.00
% from 52W High-18.18%-19.76%
All-Time High₹233.55 (Dec 14, 2020)₹100.00 (Nov 06, 2025)
% from All-Time High-25.25%-19.76%
Growth Metrics
Quarterly Revenue Growth0.15%-0.28%
Quarterly Earnings Growth0.94%-0.21%
Financial Health
Profit Margin (TTM) i0.07%0.01%
Operating Margin (TTM) i0.04%-0.02%
Return on Equity (TTM) i0.05%0.03%
Debt to Equity (MRQ) i35.5238.27
Cash & Liquidity
Book Value per Share (MRQ)₹38.54₹53.06
Cash per Share (MRQ)₹0.11₹2.88
Operating Cash Flow (TTM) i₹207.66M₹366.06M
Levered Free Cash Flow (TTM) i₹41.53M₹40.24M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i₹0.00N/A

Valuation & Enterprise Metrics Analysis: Bafna Pharmaceuticals Ltd. vs Aarey Drugs & Pharmaceuticals Ltd.

MetricBAFNAPH (Apr 24, 2026)AAREYDRUGS (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i32.3172.40
Forward P/E iN/AN/A
PEG Ratio i0.34-3.14
Price to Sales (TTM) i2.180.64
Price to Book (MRQ) i3.431.66
Market Capitalization
Market Capitalization i₹3.34B₹2.50B
Enterprise Value i₹3.53B₹3.00B
Enterprise Value Metrics
Enterprise to Revenue i2.400.77
Enterprise to EBITDA i21.81119.92
Risk & Other Metrics
Beta i-0.020.80
Book Value per Share (MRQ) i₹38.54₹53.06

Financial Statements Comparison: Bafna Pharmaceuticals Ltd. vs Aarey Drugs & Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBAFNAPH (2025)AAREYDRUGS (2025)
Revenue/Sales i1.46B4.72B
Cost of Goods Sold i1.03B4.62B
COGS % of Revenue i70.7%97.8%
Gross Profit i427.96M101.74M
Gross Margin i29.3%2.2%
Research & Development i14.54MN/A
Operating Income (EBIT) i69.62M8.08M
Operating Margin i4.8%0.2%
EBITDA i136.10M119.28M
EBITDA Margin i9.3%2.5%
Pre-Tax Income i41.53M61.02M
Pre-Tax Income % of Revenue i2.8%1.3%
Income Tax i020.78M
Income Tax % of Revenue i0.0%0.4%
Net Income (Profit) i41.53M40.24M
Profit Margin i2.8%0.9%

Balance Sheet & Liquidity Metrics

MetricBAFNAPH (2025)AAREYDRUGS (2025)
Cash & Equivalents i34.33M14.73M
Total Current Assets i847.28M2.66B
Total Current Assets % of Revenue i58.1%56.2%
Total Current Liabilities i518.52M1.49B
Total Current Liabilities % of Revenue i35.5%31.6%
Long-Term Debt i140.29M19.87M
Long-Term Debt % of Revenue i9.6%0.4%
Total Shareholders Equity i848.07M1.38B
Retained Earnings i-431.31M571.32M
Retained Earnings % of Revenue i-29.6%12.1%
Property, Plant & Equipment i192.19M1.96M

Cash Flow Statement Comparison

MetricBAFNAPH (2025)AAREYDRUGS (2025)
Operating Cash Flow i207.66M366.06M
Operating Cash Flow % of Revenue i14.2%7.8%
Capital Expenditures i-218.01M-52.04M
Free Cash Flow i2.76M50.96M
FCF Margin i0.2%1.1%
Debt Repayment iN/A-15.08M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBAFNAPHAAREYDRUGS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i23.66M28.35M
Float Shares i3.33M13.23M
% Held by Insiders i90.22%51.04%
% Held by Institutions i0.00%1.06%
% Held by Public i9.78%47.90%

Dividend Analysis & Yield Comparison: Bafna Pharmaceuticals Ltd. vs Aarey Drugs & Pharmaceuticals Ltd.

MetricBAFNAPHAAREYDRUGS
Last 12-Month Dividend i₹0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i₹0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i₹0.00N/A
Ex-Dividend DateN/AN/A